Published in Biomed Res Int on September 28, 2015
Pathogen recognition and innate immunity. Cell (2006) 44.14
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2014) 22.33
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 17.49
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
The global obesity pandemic: shaped by global drivers and local environments. Lancet (2011) 13.23
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science (2010) 12.54
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Obesity, inflammation, and insulin resistance. Gastroenterology (2007) 7.54
Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol (2013) 7.31
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem (2001) 5.61
Oxygen sensing, homeostasis, and disease. N Engl J Med (2011) 5.03
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab (2007) 4.94
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (2010) 4.76
Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes (1994) 4.66
An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A (1996) 4.57
Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell (2002) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab (2006) 3.84
Risk factors for obstructive sleep apnea in adults. JAMA (2004) 3.73
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol (2011) 3.67
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem (2003) 3.20
Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol (2009) 3.07
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (2001) 2.69
Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med (2010) 2.63
Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology (2010) 2.55
Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol (2013) 2.44
Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation (2011) 2.41
Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol (2007) 2.28
Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood (2003) 2.28
A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology (2012) 2.21
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2013) 2.20
C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia (2007) 2.19
Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab (2008) 2.12
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol (2011) 1.94
Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res (2008) 1.92
Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol (2009) 1.88
Obesity-associated liver disease. J Clin Endocrinol Metab (2008) 1.86
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One (2007) 1.77
T-ing up inflammation in fat. Nat Med (2009) 1.66
HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. J Hepatol (2011) 1.64
Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med (2014) 1.60
Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med (2007) 1.57
Chronic intermittent hypoxia predisposes to liver injury. Hepatology (2007) 1.57
Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care (2011) 1.55
HIF transcription factors, inflammation, and immunity. Immunity (2014) 1.55
Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell (2014) 1.53
Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res (2005) 1.49
Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology (2013) 1.48
Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia (2010) 1.46
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol (1985) (2011) 1.41
Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology (2011) 1.40
Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol (2006) 1.40
Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol (2013) 1.39
Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res (2011) 1.37
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol (2004) 1.36
Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol (2011) 1.35
Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) (2009) 1.22
Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res (2011) 1.22
Regulatory T cells in obesity: the leptin connection. Trends Mol Med (2010) 1.21
Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology (2009) 1.20
Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology (2011) 1.19
Obesity and respiratory diseases. Chron Respir Dis (2008) 1.17
Intermittent hypoxemia and OSA: implications for comorbidities. Chest (2015) 1.17
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev (2013) 1.14
HIFs, angiogenesis, and cancer. J Cell Biochem (2013) 1.13
Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury. Hepatology (2012) 1.13
A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med (2013) 1.13
Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med (2013) 1.10
Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut (2012) 1.10
Metabolic signatures of human adipose tissue hypoxia in obesity. Diabetes (2012) 1.10
Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr (2014) 1.09
High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med (2010) 1.05
Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol (2010) 1.03
The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int (2014) 1.03
Adipose tissue vascularization: its role in chronic inflammation. Curr Diab Rep (2011) 1.01
Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology (1982) 0.99
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis (2012) 0.93
Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep (2014) 0.92
HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation. Toxicol Lett (2014) 0.90